Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 Vaccine
NCT01084291
Completed
Dengue viruses can cause dengue fever and other serious health conditions, primarily affecting people living in tropical regions of the world. There are four types of dengue virus, and infection with one does not offer protection against the others. This study will test whether a vaccine developed to prevent infection with dengue virus type 1 (DEN1) causes a response in people's immune system and is safe.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
12/31/2012
Locations: Fletcher Allen Health Care (FAHC) General Clinical Research Center (GCRC), Burlington, Vermont +1 locations
Conditions: Dengue Virus
Register for Updates
Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects
NCT00845429
Completed
Primary Objective: To describe the immune response to a single administration of 2 formulations of the investigational cell-based influenza vaccines in healthy adult subjects. Secondary Objective: To describe the safety following a single administration of 2 formulations of the investigational cell-based influenza vaccines in healthy adult subjects.
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
12/13/2012
Locations: Not set, Hoover, Alabama +14 locations
Conditions: Influenza, Orthomyxoviruses, Myxovirus Infection
Register for Updates
Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults
NCT01215149
Completed
The purpose of this study is to evaluate the safety and tolerability of Ad26.ENVA.01 and Ad35-ENV in low-risk for HIV-uninfected healthy adults administered in heterologous and homologous prime-boost regimens at different time intervals.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
12/13/2012
Locations: Brigham and Women's Hospital, Boston, Massachusetts +5 locations
Conditions: HIV Infections
Register for Updates
A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant With Ovarian, Tubal or Peritoneal Cancer
NCT00437502
Completed
This study will evaluate the safety of administering a peptide vaccine consisting of twelve different tumor-rejection antigens known to be present on ovarian tumor cells. The vaccine is designed to elicit immune responses against twelve different pathways that are essential to tumor growth, survival and metastasis.HLA-A2+ is a required criteria for subject eligibility.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/15/2012
Locations: Duke Comprehensive Cancer Center, Durham, North Carolina
Conditions: Epithelial Ovarian, Tubal or Peritoneal Cancer
Register for Updates
A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA)
NCT01163747
Completed
This randomized, parallel-group, open-label study will evaluate the effect of Actemra (tocilizumab) on vaccination in patients with active rheumatoid arthritis who have an inadequate response to methotrexate and who have had an inadequate clinical response or were intolerant to treatment with one or more anti-tumor necrosis factor (anti-TNF) therapies.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
11/12/2012
Locations: Not set, Anniston, Alabama +46 locations
Conditions: Rheumatoid Arthritis
Register for Updates
A Model for Implementation of Cervical Cancer Screening and HPV Vaccination the Emergency Department: a Pilot Study
NCT01133509
Unknown
In this pilot study, we intend to demonstrate that a great portion of women at high risk (inadequate screening, HPV 16/18 and/or cytology) are presenting to the ED, cytology/ HPV testing via ThinPrep®Pap testTM and surveillance. We intend to provide improved access to healthcare and monitoring through administration of vaccine to eligible patients and 1 year follow up for patients involved in this study. Females meeting inclusion/exclusion criteria participating in the study (n=100) that have n... Read More
Gender:
FEMALE
Ages:
Between 18 years and 26 years
Trial Updated:
08/21/2012
Locations: Sentara Norfolk General Hospital, Norfolk, Virginia
Conditions: Genital Human Papilloma Virus Infection
Register for Updates
A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX
NCT00319592
Completed
The purpose of this study is to determine non-inferiority in seroconversion and to compare the safety and tolerability between ChimeriVax™-JE and JE-VAX® to the respective homologous virus strain and several wild types strains after completion of vaccination course.
Gender:
ALL
Ages:
Between 18 years and 48 years
Trial Updated:
08/16/2012
Locations: Clinical Pharamacology Center, Lenexa, Kansas
Conditions: Japanese Encephalitis
Register for Updates
Vaccine Therapy in Treating Patients With Stage D0 Prostate Cancer
NCT00514072
Unknown
RATIONALE: Vaccines made from tumor cells may help the body build an effective immune response to kill tumor cells. PURPOSE: This randomized phase II trial is studying vaccine therapy to see how well it works compared with a placebo in treating patients with stage D0 prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/08/2012
Locations: Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland
Conditions: Prostate Cancer
Register for Updates
Safety and Efficacy of an H1N1 Influenza Vaccine in People With Asthma
NCT00978120
Completed
The purpose of this study is to assess the safety and the body's immune response (body's defense against disease) to an experimental H1N1 influenza vaccine in people with asthma. The study will enroll 350, and possibly up to 400 healthy adults ages 12 and older with mild, moderate, or severe asthma. Participants will be randomly assigned to 1 of 2 possible vaccine groups: group 1 will receive 15 mcg of H1N1 vaccine; group 2 will receive 30 mcg of H1N1 vaccine given as two 15 mcg injections. Both... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/08/2012
Locations: Emory University, Atlanta, Georgia +6 locations
Conditions: H1N1 Influenza Virus
Register for Updates
Sanofi H1N1 + TIV - Adults and Elderly
NCT00943878
Completed
The purpose of this study is to assess the safety and immune response (body's defense against disease) to an experimental H1N1 influenza vaccine against the 2009 H1N1 virus. This study will help determine how the H1N1 flu shot should be given with the seasonal flu shot to make it most effective. Participants will include up to 850 healthy adults, ages 18 and older. Participants will receive 2 H1N1 vaccines in addition to placebo (inactive substance) and the seasonal flu shot over 3 study visits... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/26/2012
Locations: Emory Vaccine Center - The Hope Clinic, Decatur, Georgia +4 locations
Conditions: Influenza
Register for Updates
Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older
NCT00976027
Terminated
The aim of this study is to determine the efficacy of Fluzone High Dose vaccine and that of Fluzone® vaccine in the elderly. Primary objective: To measure the efficacy of the vaccine, defined as the prevention of laboratory-confirmed influenza caused by viral types/subtypes that are antigenically similar to those contained in the respective annual vaccine formulations. Secondary objectives: * To compare the clinical efficacy of Fluzone High Dose vaccine with that of Fluzone® vaccine in elder... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/24/2012
Locations: Not set, Birmingham, Alabama +97 locations
Conditions: Influenza
Register for Updates
PR1 Vaccination in Myelodysplastic Syndrome (MDS)
NCT00893997
Terminated
Primary aim: 1. To determine the immunologic response, using a PR1-HLA-A2 tetramer assay, to 4 subcutaneous (SQ) injections of TVC-PR1 vaccine formulated in Montanide ISA 51 VG followed by granulocyte macrophage colony-stimulating factor (GM-CSF) in low risk and intermediate-1 myelodysplastic syndrome (MDS) patients. Secondary aims: 1. To determine if non-immunologic responders to 4 subcutaneous (SQ) injections of TVCPR1 vaccine formulated in Montanide ISA 51 VG followed by GM-CSF can be conv... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2012
Locations: U.T. M.D. Anderson Cancer Center, Houston, Texas
Conditions: Leukemia, Myelodysplastic Syndrome
Register for Updates